Numerical Improvement in OS, PFS Noted With Avelumab Vs Chemotherapy in Advanced PD-L1+ NSCLC - Cancer Network

The phase 3 JAVELIN Lung did not produce statistically significant overall or progression-free survival benefit with avelumab for non–small cell lung cancer.

Despite longer progression-free and overall survival (OS) observed in patients with PD-L1positive nonsmall cell lung cancer who were treated with avelumab (Bavencio) vs platinum-based chemotherapy, r… [+7943 chars]

full article...